Premium
A study of the potential interactions between azapropazone and frusemide in man.
Author(s) -
Williamson PJ,
Ene MD,
Roberts CJ
Publication year - 1984
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1984.tb02515.x
Subject(s) - pharmacology , medicine , intensive care medicine
Ten healthy individuals received frusemide 40 mg orally for 7 days. Following a drug free period of 7 days they received azapropazone 600 mg twice daily for 7 days and then both treatments for a further 7 days. Sodium excretion fell from 141 +/‐ 16.8 mmol/day to 84.3 +/‐ 6.8 mmol/day (P less than 0.01) on initiation of azapropazone treatment. The natriuretic response to frusemide was unchanged by premedication with azapropazone. Urate excretion rose from 3.35 +/‐ 0.249 mmol/day to 4.98 +/‐ 0.365 mmol/day on initiation of azapropazone therapy but subsequently returned to baseline values. Plasma uric acid fell from 0.289 +/‐ 0.024 mmol/l to 0.167 +/‐ 0.0125 mmol/l (P less than 0.001) on azapropazone but rose to 0.186 +/‐ 0.0116 mmol/l (P less than 0.001) with the addition of frusemide. Azapropazone may cause sodium retention but after repeated administration frusemide still has a marked diuretic action. The hypouricaemic effect of azapropazone is only slightly antagonised by frusemide at the doses studied.